I work in the Research Development team as a Senior Research Information Co-ordinator. I graduated from the University of Nottingham with a PhD in Chemistry in 2020. After finishing my PhD, I joined an R&D company based in Nottingham where I spent my time synthesising potential new drug treatments for a wide variety of diseases. As part of my role I will help the team communicate the latest MND research on this blog, as well as on our twitter page (@MNDResearch).
Reading Time: 5 minutes 8 years ago, the International Day of Women and Girls in Science was created to improve gender equality in science and recognise the invaluable role women play. Each year the world comes together to celebrate inspirational women of the past, present, and future. While women continue to be under-represented in science globally, the conversation of…
Reading Time: 5 minutes 8 years ago, the International Day of Women and Girls in Science was created to improve gender equality in science and recognise the invaluable role women play. Each year the world comes together to celebrate inspirational women of the past, present, and future. While women continue to be under-represented in science globally, the conversation of gender equality in science is much louder than it was.
Reading Time: 3 minutes When you think of scientific research most people will immediately imagine a laboratory with scientists in white lab coats, however MND research takes many forms. As well as research that looks for effective treatments, it is also important to investigate ways to improve the well-being of people living with MND and their carers/family members.
Reading Time: 5 minutes The top-line results of the Modifying Immune Response and OutComes in ALS (MIROCALS) clinical trial were announced on 6 December 2022 at the 33rd International Symposium on ALS/MND. As part of the clinical trials session, the scientific leads Dr Gilbert Bensimon and Professor Nigel Leigh discussed the study design and outcomes (C03). MIROCALS was an 18-month,…
Reading Time: 5 minutes This blog is part of our Symposium Blogathon series – where we are counting down to the 33rd International Symposium. Numbers in bold blue type correspond to the code in the abstract book. Click on the number to be redirected to the full abstract. Clinical trials are research studies in human volunteers that determine whether…
Reading Time: 5 minutes This blog is part of our Symposium Blogathon series – where we are counting down to the 33rd International Symposium. Numbers in bold blue type correspond to the code in the abstract book. Click on the number to be redirected to the full abstract. Clinical trials are research studies in human volunteers that determine whether…
Reading Time: 7 minutes This blog is part of our Symposium Blogathon series – where we are counting down to the 33rd International Symposium. Numbers in bold blue type correspond to the code in the abstract book. Click on the number to be redirected to the full abstract. Every year, one of the highlights of the Symposium is our…
Reading Time: 6 minutes This blog is part of our Symposium Blogathon series – where we are counting down to the 33rd International Symposium. Numbers in bold blue type correspond to the code in the abstract book. Click on the number to be redirected to the full abstract. Every year, one of the highlights of the Symposium is our…
Reading Time: 6 minutes On Tuesday 4 October 2022, a new paper was published which investigated the risk of developing a neurodegenerative disease, such as MND, among former Scottish international rugby players. The paper concluded that former Scottish international rugby union players had an increased risk of developing MND compared to the general population. We sat down with Dr…
Reading Time: 6 minutes On 29th September 2022 AMX0035, a treatment for Motor Neurone Disease (MND) was approved by the Food and Drug Administration (FDA) in the United States. Two countries have approved AMX0035, with Canada conditionally approving the drug, known there as Albrioza, back in June 2022. The Canadian approval is dependent on the results of the ongoing…
